Log In

Forgot Password?


Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Metabolic Brain Changes Across Different Levels Of Cognitive Impairment In ALS: A 18F-FDG-PET Study
Neuromuscular and Clinical Neurophysiology (EMG)
S20 - Motor Neuron Disease/Amyotrophic Lateral Sclerosis (2:32 PM-2:40 PM)

PET scanning using the 18F-2-fluoro-2-deoxy-D-glucose ligand (18F-FDG-PET) is a marker of neurodegeneration and neuronal injury in vivo.

To identify the metabolic changes related to the various levels of cognitive deficits in ALS using 18F-FDG-PET imaging. 

 274 ALS patients underwent neuropsychological assessment and brain 18F-FDG-PET at diagnosis. According to the criteria published in 2017, cognitive status was classified as: ALS with normal cognition (ALS-Cn, n=132), ALS with behavioural impairment (ALS-Bi, n=66), ALS with cognitive impairment (ALS-Ci, n=30), ALS with cognitive and behavioural impairment (ALS-Cbi, n=26), ALS with Frontotemporal Dementia (ALS-FTD, n=20). We compared each group displaying some degree of cognitive and/or behavioural impairment to ALS-Cn patients, including age at PET, sex, and ALSFRS-R as covariates. 

We identified frontal lobe relative hypometabolism in cognitively impaired patients that resulted more extensive and significant across the continuum from ALS-Ci, through ALS-Cbi, to ALS-FTD. ALS-FTD patients also showed cerebellar relative hypermetabolism. ALS-Bi patients did not show any difference compared to ALS-Cn. 

These data support the concept that patients with cognitive impairment have a more widespread neurodegenerative process compared to patients with a pure motor disease: the more severe the cognitive impairment, the more diffuse the metabolic changes. Otherwise, metabolic changes related to pure behavioural impairment need further characterization.

Antonio Canosa
Antonio Canosa has nothing to disclose.
Cristina Moglia (University of Torino) Cristina Moglia has nothing to disclose.
Umberto Manera, MD (Department of Neuroscience "Rita Levi Montalcini" - University of Torino) Dr. Manera has nothing to disclose.
Rosario Vasta, MD (University of Turin, Department of Neurosciences) Dr. Vasta has nothing to disclose.
Maria Claudia Torrieri Maria Claudia Torrieri has nothing to disclose.
Vincenzo Arena Vincenzo Arena has nothing to disclose.
Fabrizio D'Ovidio Fabrizio D'Ovidio has nothing to disclose.
Francesca Palumbo Francesca Palumbo has nothing to disclose.
Jean Pierre Zucchetti Jean Pierre Zucchetti has nothing to disclose.
Barbara Iazzolino Barbara Iazzolino has nothing to disclose.
Laura Peotta Laura Peotta has nothing to disclose.
Andrea Calvo, MD, PhD, FAAN (Dept. of Neuroscience, University of Turin) Dr. Calvo has nothing to disclose.
Marco Pagani Marco Pagani has nothing to disclose.
Adriano Chio, MD, FAAN (Dept. of Neuroscience, University of Turin) Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen.